Regeneron Pharmaceuticals, Inc.

(NASDAQ Global Select)
Back to all articles
Very Bullish +78

US FDA approves Regeneron’s gene therapy, Otarmeni for genetic hearing loss

AI-generated analysis

🎧 The US FDA granted accelerated approval for Otarmeni, Regeneron's first-in-class gene therapy for OTOF-related genetic hearing loss.

🌐 Otarmeni is a one-time adeno-associated virus vector-based treatment intended for children and adults with severe-to-profound sensorineural hearing loss from confirmed OTOF gene variants.

🆓 Regeneron announced the therapy will be provided free of charge to eligible patients in the United States under the National Priority Voucher program.

🔬 Efficacy data from the pivotal CHORD trial showed 80% of participants achieved a hearing threshold of 70 dB HL or better at 24 weeks post-dose.

📉 All prior responders maintained their hearing improvements through week 48, with 42% achieving normal hearing capable of detecting whispers (25 dB HL).

🧬 The therapy targets the lack of functional otoferlin protein in inner ear sensory cells, historically considered a permanent condition requiring lifelong assistive devices.

⚠️ Treatment is not recommended for patients where preoperative imaging shows access to the inner ear is not feasible due to abnormal anatomy or mastoid pneumatization.

🧑‍⚕️ The surgical administration resembles cochlear implantation and can be performed in young infants by surgeons trained specifically in Otarmeni delivery.

💊 Approval was based on average pure tone audiometry results at week 24, with continued approval contingent upon the confirmatory portion of the CHORD trial.

🤝 Experts described the breakthrough as enabling reinstatement of natural hearing, allowing patients to respond to voices and interact with their environment without implants.

⚠️ Common adverse reactions observed in the safety population included otitis media, vomiting, nausea, dizziness, procedural pain, gait disturbance, and nystagmus.

🎯 Otarmeni was formerly known as DB-OTO before receiving FDA approval for this specific indication of genetic hearing loss.

🩺 The condition affects approximately 50 newborns per year in the US and is an ultra-rare disorder affecting only about 0.5% of those with congenital hearing loss.

🎤 Advocacy groups emphasize that while new treatments offer options, families should assess all available approaches including cochlear implants to find what suits their circumstances.

🏗️ The therapy marks a significant advancement in gene editing and delivery, utilizing the National Priority Voucher program to accelerate approval for rare diseases.

Bullish Signals
  • The US FDA granted accelerated approval for Regeneron's gene therapy, Otarmeni, marking it as the first gene therapy and second new molecular entity approved under the FDA Commissioner's National Priority Voucher program.
  • Otarmeni represents a groundbreaking first-in-class in vivo gene therapy for OTOF-related hearing loss, offering a one-time treatment that reinstates natural 24/7 hearing for patients with severe-to-profound sensorineural hearing loss.
  • In the pivotal CHORD trial, 80% of participants (16 of 20) experienced hearing improvements at week 24, achieving the primary endpoint of a threshold of <=70 dB HL without requiring cochlear implantation.
  • For those followed to 48 weeks, all prior responders maintained their response to therapy, and 42% of participants (5 of 12) achieved normal hearing levels including whispers (<=25 dB HL).
  • Regeneron will make Otarmeni available for free in the US, demonstrating a commitment to accessibility as the first company to offer such a gene therapy advance without cost.
  • The therapy allows use in young infants through a surgical procedure similar to cochlear implantation and demonstrates rapid, meaningful hearing responses witnessed by clinical trial investigators.
  • Otarmeni addresses ultra-rare OTOF-related hearing loss affecting approximately 50 newborns per year in the US, potentially transforming lives previously considered permanently affected by genetic hearing loss.
Risk Factors
  • Continued approval of Otarmeni is contingent upon verification and description of clinical benefit in the confirmatory portion of the CHORD clinical trial.
  • The therapy is not recommended for patients where preoperative imaging shows access to the inner ear is not feasible, such as those with abnormal mastoid pneumatization or significant anatomic variations.
  • Otarmeni was granted accelerated approval based on hearing sensitivity improvement at week 24, though long-term durability and efficacy beyond this period require further confirmation.
  • Only a subset of trial participants achieved normal hearing (including whispers); specifically, only 42% of all participants followed to 48 weeks reached this threshold.
  • The most common adverse reactions observed in the safety population include otitis media, vomiting, nausea, dizziness, procedural pain, gait disturbance, and nystagmus.
  • The therapy requires administration by a surgeon experienced in intracochlear surgery using a procedure similar to cochlear implantation, limiting immediate accessibility to only specialized surgical centers.
  • Otarmeni is indicated specifically for patients with preserved outer hair cell function, excluding a broader population of OTOF-related hearing loss cases where this condition may not be met.
Full Analysis
The U.S. Food and Drug Administration (FDA) has granted accelerated approval for Regeneron Pharmaceuticals' gene therapy, Otarmeni (lunsotogene parvec-cwha), marking a significant advancement in treating genetic hearing loss. This is the first gene therapy approved under the FDA Commissioner's National Priority Voucher program and is specifically indicated for pediatric and adult patients with severe-to-profound sensorineural hearing loss associated with biallelic variants in the OTOF gene. Otarmeni, which replaced the former designation DB-OTO, is an adeno-associated virus vector-based therapy designed to restore natural hearing by reinstating otoferlin protein function within the inner ear. The treatment is being made available free of charge in the United States and is intended for patients who have not previously received a cochlear implant in the affected ear and whose outer hair cell function is preserved. Efficacy data from the pivotal CHORD clinical trial demonstrated that among 20 participants aged 10 months to 16 years, 80% (16 of 20) experienced hearing improvements reaching a threshold of ≤70 dB HL at 24 weeks after a single intracochlear infusion dose. Additionally, 70% (14 of 20) demonstrated an auditory brainstem response indicating hearing function at ≥90 decibels, and by week 48, all prior responders maintained their improvement, with 42% achieving normal hearing levels including whispers at ≤25 dB HL. The approval is contingent upon further verification of clinical benefit through the confirmatory portion of the CHORD trial, which is currently ongoing to include more patients. The therapy is not recommended for patients where preoperative imaging indicates that access to the inner ear is not feasible due to abnormal mastoid pneumatization or significant anatomic variations of the middle and inner ears. Common adverse reactions observed in the safety population included otitis media, vomiting, nausea, dizziness, procedural pain, gait disturbance, and nystagmus, all occurring in less than 5% of cases. Regeneron's Chief Scientific Officer, George D. Yancopoulos, described the approval as a "huge scientific leap" intended to benefit humanity, while the FDA emphasized that continued use may depend on confirming long-term benefits. Otarmeni represents a pivotal shift for families managing ultra-rare genetic hearing loss conditions, offering the possibility of reinstating natural listening abilities without lifelong dependence on amplification devices alone.